Trials / Completed
CompletedNCT00251459
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5,000 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuFab V2 (ranibizumab) |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-09-01
- First posted
- 2005-11-10
- Last updated
- 2014-03-10
Source: ClinicalTrials.gov record NCT00251459. Inclusion in this directory is not an endorsement.